Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. DeLauro’s FDA Focus: “Restore” Oversight, Increase Budget

This article was originally published in The Tan Sheet

Executive Summary

Rep. Rosa DeLauro (D-Conn.), poised to take the helm of the House subcommittee with oversight of FDA's budget, hopes to increase agency funding, but not without the tradeoff of enhanced congressional supervision of how FDA performs its duties

You may also be interested in...

Democrats Expected To Put Supplement, Drug Regulation Under Microscope

Increased scrutiny of issues including the safety of dietary supplements and phenylephrine efficacy is likely as senior Democrats move into leadership roles on Congressional committees following the 2006 midterm elections

DeLauro Bill Calls For FDA Plan B Workshop To Discuss Sub-18 Data

A bill to be filed Sept. 26 by Rep. Rosa DeLauro (D-Conn.) would require that FDA hold a scientific workshop to examine data on the use of Plan B emergency contraceptive in women under age 18

Study Shows No Death, MI Advantages For Stenting Over Medical Therapy

Results form the 2,287-patient COURAGE trial presented the American College of Cardiology meeting should give physicians more to think about before moving forward with percutaneous coronary intervention in stable heart disease patients, researchers say.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts